Trading update: Here's why the Livetiles share price is up today

Livetiles Ltd (ASX:LVT) is growing its top line nicely.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Livetiles Ltd (ASX: LVT) share price is up 2% to 57 cents today after the software company that "empowers its users to create their own intelligent workplace experiences" today reported an operating cash loss of $7.76 million on revenue of $5.2 million for the quarter ending March 31 2019.

In total for the nine months ending March 31 2019 it has posted an operating cash loss of $28.4 million and had cash on hand of $21.1 million at the quarter end.

On the positive side it did report that annualised recurring revenue (ARR) more than tripled over the past year to $34.5 million, while the aforementioned quarterly operating cash loss was actually a 19% improvement on the loss booked in the prior quarter.

The group also has an ambitious 'target' of growing ARR to $100 million by June 30 2021.

Targets are all well and good, but it's executing on them that counts and which way the Livetiles share price heads in the future will largely depend as much on its cost control as its top line growth.

The stock has generally been on a long-term upward trajectory over the past 5 years thanks to the recurring revenue growth, although considering the cash burn over the past 9 months is now greater than cash on hand investors might want to consider the possibility of a capital raising down the line.

Motley Fool contributor Tom Richardson has no position in any of the stocks mentioned. You can find Tom on Twitter @tommyr345 The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Share Gainers

3 ASX All Ords shares up 50%+ in March

These ASX shares have been on fire this month. But why?

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Share Gainers

Why Mesoblast, Patriot Battery Metals, Sigma, and Zip shares are pushing higher

These shares are having a good session on hump day. But why?

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Consumer Staples & Discretionary Shares

If you'd put $20,000 in this ASX retail stock at the start of 2023, you'd have $134,000 now

This online retailer has executed a remarkable turnaround for its investors.

Read more »

Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
Share Gainers

Here are the top 10 ASX 200 shares today

It was back to earth for ASX shares this Tuesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »